Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the
Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good
General Health
Phase:
Phase 1
Details
Lead Sponsor:
International AIDS Vaccine Initiative
Collaborator:
Biomedical Advanced Research and Development Authority